Investor

The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP)

Last cheque observed Nov 2023. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietGrowth equity

Series C

Cheques on record
0%of best year0cheques in 12 months, 2 on record
Since the last cheque1090days00hrs00min00sec
Median round$59MRounds led0 of 2
Pitch The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP)

The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) highlights

  1. 01

    2 rounds on record

  2. 02

    Mostly Series C: 100% of its rounds

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Cold pitches
Not stated

The record

Every round we can evidence, newest first2 appearances

  1. 2023

    1 round

  2. Nov
    Vittoria BiotherapeuticsUS · Tellus BioVentures$15MWith 7 others
  3. 2020

    1 round

  4. Mar
    Kymera TherapeuticsSeries C · US · Hatteras Venture Partners$102MWith 7 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Recently backed

The latest companies The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) put money into.

Kymera Therapeutics$102M · Mar 2020

Quick answers about The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP)

What does The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) invest in?

The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) invests most often at Series C (100% of the rounds on record).

How active is The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP)?

2 investments on record, 0 of them in the last 12 months. The most recent was in Nov 2023.

What has The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) invested in recently?

Its most recent investments on record: Vittoria Biotherapeutics (Undisclosed round, Nov 2023) and Kymera Therapeutics (Series C, Mar 2020).

How big are The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP)'s cheques?

The median round it joins is $59M.

Is The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) investing now?

No investments in the last 12 months; the latest was in Nov 2023.

What kind of investor is The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP)?

The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) is a growth equity firm.

Where does this information on The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) come from?

From 2 articles and filings naming it in a round, public registers and its own website, checked and rebuilt every night.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it